Abstract
Hereditary cancer genetics is increasingly recognized as an integral component of cancer care, contributing to treatment, early detection, and risk reduction strategies for patients and their relatives. In this context, several hereditary cancer programs, databases, recommendations, and guidelines have been implemented within the Italian National Health System and at hospital level. However, independent and specific quality indicators for hereditary tumor management are still lacking, limiting the ability to evaluate activities across individual centers. To address this gap, AIFET (Associazione Italiana Familiarità ed Ereditarietà Tumori) has established a dedicated scientific committee for the development of such quality indicators. Here, for the first time to our knowledge, we present a set of 37 quality indicators derived from a national Italian survey. The indicators were organised into four sections: General indicators (applicable to all syndromes), specific to hereditary breast and ovarian cancer, specific to colorectal cancer and polyposis, specific to melanoma predisposition. By promoting consistency across centres, this model may not only enhance the quality of care nationally but also foster collaboration with European institutions toward shared standards in hereditary cancer management.
Get full access to this article
View all access options for this article.